Uses of Clopistad

Clopidogrel contains the active ingredient Clopidogrel, an antiplatelet agent used in the prevention of cardiovascular events due to thrombosis. The following article will provide readers with some basic information about indications, dosage, side effects and notes when using Clopistad.

Clopidogrel is a prodrug and needs to be converted to the active substance in the body. The active metabolite inhibits the P2Y12 component of the ADP receptor on the platelet surface, prevents the activation of the GPIIb/IIIa complex, and inhibits platelet aggregation.
Inhibition of platelet aggregation is dose dependent. This effect can be seen 2 hours after the dose of clopidogrel monotherapy. Repeated doses of clopidogrel 75 mg daily significantly inhibited ADP-induced platelet aggregation and reached steady state between days 3 and 7. After reaching steady-state, inhibition was moderate with 75 mg. /day is about 40-60%. Platelet aggregation and bleeding time may gradually return to normal within about 5 days after stopping treatment.

Clopistad is indicated for use in the following cases:
Prevention of arterial thrombotic events; Use in adult patients with acute coronary syndromes; Prevention of arterial thrombotic and thromboembolic events in patients with atrial fibrillation.

Clopistad is taken orally before or after a meal. Specific dosage is as follows:
Adults and the elderly: Use with a dose of Clopistad 75 mg / day. Patients with acute coronary syndromes without ST-segment elevation: A loading dose of 300 mg should be initiated as a single dose and then maintained at 75 mg once daily in combination with aspirin 75 - 325 mg/day. day). Acute ST-segment elevation myocardial infarction: A 300 mg loading dose with aspirin and with or without a fibrinolytic agent should be initiated, followed by a maintenance dose of 75 mg/day. For patients over 75 years of age, a loading dose should not be used at the beginning of treatment. Patients with atrial fibrillation: The recommended dose of Clopidogrel is 75 mg/day. Patients should note that the above dosage is for reference only. The specific dose will vary depending on the condition and severity of the disease. You should consult a specialist for the right dosage.

Clopidogrel overdose can lead to bleeding. If the patient experiences bleeding, appropriate therapy should be instituted immediately. There is currently no specific antidote in the case of an overdose of Clopidogrel. If prompt correction of prolonged bleeding time is required, the physician may prescribe platelet transfusions to reduce the effect of clopidogrel.
5. Contraindications of Clopidogrel Drug Clopistad is contraindicated in the following cases:
Patients with hypersensitivity to Clopidogrel or any other ingredient of the drug; Existing bleeding conditions such as peptic ulcer, intracranial hemorrhage; Severe liver failure. 6. Undesirable effects of the drug Clopistad Drug Clopistad can cause some unwanted effects as follows:
Hematology: Severe bleeding (≤4%), minor bleeding (4-5%); Cardiovascular: Hemorrhagic stroke, hypotension, vasculitis; Nervous system: Intracranial hemorrhage; Dermatological: Acute exanthematous pustulosis, bullous rash, eczema, urticaria, erythema multiforme, psoriasis, exfoliative dermatitis, vesicular eruption, maculopapular rash, pruritus, Stevens syndrome -Johnson, toxic epidermal necrolysis; Digestive: Colitis, diarrhea, peptic ulcer, pancreatitis, stomatitis; Liver: Acute liver failure, hepatitis; Hypersensitivity: Angioedema, anaphylaxis, serum sickness; Nervous system: Confusion, hallucinations, headache; Musculoskeletal: Joint pain, arthritis; Renal: Increased serum creatinine; Respiratory: Bronchospasm, eosinophilic pneumonia, interstitial pneumonia; Other: Fever.

Notes when using Clopistad include:
If during the course of treatment, the patient sees clinical signs suggestive of bleeding, they must immediately go to the nearest medical facility; Clopidogrel should be used with caution in patients at risk of bleeding such as recent surgery, trauma or other medical conditions; The use of Clopidogrel with Aspirin increases the risk of major bleeding and all-cause mortality; For patients with coronary stents, early discontinuation of treatment may lead to thrombosis and myocardial infarction; Thrombocytopenia bleeding has been reported very rarely after clopidogrel administration. This condition sometimes occurs after only a short time of taking the drug. This is a life-threatening condition and requires immediate treatment; Adverse effects such as dizziness, lightheadedness, headache and eye bleeding (uncommon) have been reported with clopidogrel. Patients experiencing these side effects should not drive or operate machinery; The risk of birth defects and miscarriage is not related to the use of clopidogrel in the mother. Existing guidelines recommend using Clopidogrel only when absolutely necessary and for the shortest possible time until more safety data are available. Discontinue clopidogrel 5 to 7 days before labor to prevent maternal bleeding. It is not known whether Clopidogrel passes into breast milk. Adverse events have not been reported in breastfed infants due to limited data. According to the manufacturer, the decision to breastfeed during treatment should weigh the risks and benefits to make an appropriate decision. Concomitant use of Clopistad with certain other drugs may reduce the effectiveness of treatment or increase dangerous side effects. Therefore, patients are advised to inform their doctor of all medications they are taking for appropriate advice. In summary, Clopistad is an antiplatelet agent used for the prevention of thrombotic cardiovascular events. The drug can cause many dangerous side effects, especially bleeding. Therefore, patients need to strictly follow the doctor's instructions and monitor for abnormal signs during the drug use.